Skip to content

Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure

Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02903225
Acronym
REINCA
Enrollment
40
Registered
2016-09-16
Start date
2010-04-30
Completion date
2014-11-30
Last updated
2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Systolic Heart Failure

Keywords

Heart rate variability, Systolic heart failure, Physical exercise, Parasympathetic indexes

Brief summary

Controlled exercise training is a valuable therapeutic addition to pharmacological treatment in most patients with chronic heart failure, reducing long-term mortality, preventing cardiac remodeling and improving functional capacity. Despite the mechanism underlying its benefits might be multifactorial, a sustained improvement in autonomic balance is usually attributed as a major effect. Nevertheless, not all eligible subjects show the same response to exercise, probably due to several differences in the subpopulations enrolled. The investigators hypothesize that some Heart Rate Variability indexes could be valid tools to optimize the selection and follow-up of chronic heart failure patients to training

Detailed description

Forty subjects followed in a University Heart Failure Management Program were prospectively included. All patients were evaluated before the randomization and after 24 weeks from enrollment. The investigators performed a detailed anamnesis and complete physical examination, Doppler echocardiography, Stress Testing, 6-minute walk test, heart rate variability analysis, and quality of life test. Patients were randomized either to a training group: performing a supervised training program, or a control group receiving usual care. All patients received an optimal pharmacologic treatment including diuretics, angiotensin converting enzyme inhibitors or angiotensin receptor blockers and beta-adrenergic blocking agents. All patients included in the training group attended a supervised program 3-days/week during 24 weeks (68-74 sessions). Physical aerobic training appears to impart beneficial changes in autonomic control of patients with chronic heart failure through both parasympathetic and sympathetic control of hear rate. These effects produce changes in several Heart Rate Variability indices as HF and rMSSD related with parasympathetic tone.

Interventions

BEHAVIORALCardiac Rehabilitation

All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity

Sponsors

Universidad de la Republica
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* subjects followed in a University Heart Failure Management Program * maintained sinus rhythm * New York Heart Association Functional Class (NYHA) I to III and * LVEF≤40% documented by echocardiogram * optimal pharmacologic treatment

Exclusion criteria

* history of stroke, myocardial infarction or extended anterior myocardial scar * revascularization procedures or recurrent angina within previous 3 months * orthopedic impairment * alcohol or drug abuse; * implant of pacemaker or cardioverter-defibrillator (AICD); * frequently ventricular dysrhythmias, * atrial flutter or fibrillation * insulin-dependent diabetes mellitus; * severe chronic obstructive pulmonary disease or renal dysfunction * comorbid non-cardiac disease limiting short term survival * previous enrollment in an ET program * subjects at great propensity for noncompliance

Design outcomes

Primary

MeasureTime frameDescription
Clinical Events6 monthChange in New York Heart Association Functional Class; Number of hospitalizations 6 months before and after the date of enrollment; temporary or permanent withdrawal from the study protocol (due to persistent atrial or ventricular arrhythmias; worsening of congestive heart failure symptoms; myocardial infarction; unstable angina; need of cardiac interventions: pacemaker, implantable cardioverter defibrillator, coronary revascularization or cardiac transplantation; stroke or transient ischemic attack; severe peripheral intermittent claudication or death observed during training or follow-up sessions
Mean heart rate6 monththe mean value of the12-min Electrocardiogram-recordings was considered the resting heart rate (beats per minute)
6 minute walk test6 monthwalking along a 20-meter long corridor at their own pace, with the aim of covering as much ground as possible in 6 minutes. The distance walked was expressed in meter
left ventricular ejection fractionone yearThe area-length method was measured to obtain biplane left ventricle volumes. Left Ventricle ejection fraction was derived from the standard equation (%)
quality of life6 monthAll the subjects completed the Short-Form 36 Health Survey (SF-36), available in its Spanish version, for measuring physical and mental quality of life
Stress Test6 monthsymptom limited exercise testing, measured in metabolic unit (MET)
square root of the mean squared successive differences of R-R intervals (rMSSD)6 monthshort-term continuous electrocardiographic recordings were performed for heart rate variability analysis. In the time domain, the square root of the mean squared successive differences of R-R intervals (rMSSD) were calculated. Units: ms
Heart rate power high-frequency (HF)6 monthThe high-frequency (HF), from 0.15 to 0.40 Hz of the power spectral analysis were calculated. Units: ms2/Hz

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026